Trials / Completed
CompletedNCT03582098
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
A Retrospective Observational Study to Evaluate the Clinical Outcomes and Routine Management of Patients With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 112 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idelalisib | Tablets were administered in accordance with the marketing authorization. |
| DRUG | Rituximab | Tablets were administered in accordance with the marketing authorization. |
Timeline
- Start date
- 2018-09-12
- Primary completion
- 2019-03-26
- Completion
- 2019-03-26
- First posted
- 2018-07-10
- Last updated
- 2019-04-12
Locations
16 sites across 2 countries: Ireland, United Kingdom
Source: ClinicalTrials.gov record NCT03582098. Inclusion in this directory is not an endorsement.